Treatment breakdown of the patients with MM cohort. (A) Flowchart showing that the initial retrospective query yielded 115 patients with RRMM enrolled in a BiAb clinical trial at Mount Sinai Hospital. Of these 115 patients, we focused on 58 patients who came off the trials and received salvage therapy, including other T-cell redirection therapies, chemotherapy, and triplet regimens. (B) Clinical outcomes of therapies administered to 58 patients as FST and breakdown of treatments given to 37 patients as SST.